Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia SAD Study of EB070 in Healthy Volunteers
NCT07413536Phase 1Not yet recruiting
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of EB070 in asthma (10 arms). Primary endpoint: Adverse Events. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
EB070
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07413536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07413536.